4 results
To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of nelarabine, etoposide and cyclophosphamide when given in combination to children with T-ALL and bone marrow relapse or T-LL.
The effect of correction of metabolic acidosis in chronic kidney disease on intrarenal RAS activity.
Primary Objective: - To study if sodiumbicarbonate therapy in patients with metabolic acidosis due to chronic kidney disease diminishes intrarenal RAS activity (without affecting the systemic RAS).Secondary Objective(s): - To study if…
To assess the safety and biodistribution of 89Zr-MEDI4736 and its uptake in tumor and target irAE tissues.
Primary Objective:Part 1: To identify a dose of AMG 479 in combination with etoposide plus carboplatin and/or etoposide plus cisplatin, and of AMG 102 in combination with etoposide plus carboplatin and/or etoposide plus cisplatin that can be…